OncoMatch

OncoMatch/Clinical Trials/NCT06162221

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

Is NCT06162221 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments for non-small cell lung cancer, nsclc.

Phase 1/2RecruitingRevolution Medicines, Inc.NCT06162221Data as of May 2026

Treatment: RMC-6291 · RMC-6236 · Pembrolizumab · Cisplatin · Carboplatin · Pemetrexed · RMC-9805 — The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors as a monotherapy or combined with Standard(s) of Care (SOC) or with each other. The first four subprotocols include the following: Subprotocol A: RMC-6291 +/- RMC-6236 + SOC Subprotocol B: RMC-6236 + SOC Subprotocol C: RMC-9805 +/- RMC-6236 + SOC Subprotocol D: RMC-9805

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Small Cell Lung Carcinoma

Tumor Agnostic

Biomarker criteria

Required: KRAS G12C mutation

KRAS G12C-mutated solid tumor malignancy (Subprotocol A)

Required: KRAS G12D mutation

RAS G12D-mutated NSCLC (Subprotocol C and Subprotocol D)

Required: NRAS mutation

RAS-mutated NSCLC (Subprotocol B)

Required: HRAS mutation

RAS-mutated NSCLC (Subprotocol B)

Required: KRAS mutation

RAS-mutated NSCLC (Subprotocol B)

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Min 1 prior line

Must have received: standard therapy — appropriate for tumor type and stage

Received prior standard therapy appropriate for tumor type and stage

Lab requirements

Blood counts

Kidney function

Liver function

Adequate organ function as outlined by the study

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Banner MD Anderson Cancer Center · Gilbert, Arizona
  • City of Hope - Duarte · Duarte, California
  • City of Hope - Lennar · Irvine, California
  • UC Davis, Davis Comprehensive Cancer Center · Sacramento, California
  • University of California, San Diego Moores Cancer Center · San Diego, California

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify